Plexin D1 as a Potential Biomarker inPM/DM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-25

Study Completion Date

2024-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

evaluation of level of serum circulating plexin D1 on extacellular vesicles in adult PM/DM patients and juvenile dermatomysitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers of Cancer-Associated Myositis

NCT06808672

Dermatomyositis

ACTIVE_NOT_RECRUITING

Coagulation Activation in Patients With Pemphigus

NCT06285435

Pemphigus

NOT_YET_RECRUITING

Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis

NCT00667134

Systemic Sclerosis

COMPLETED

Role of Eosinophil in Fibrogenesis of Systemic Sclerosis

NCT03816189

Systemic Sclerosis Systemic Scleroderma

COMPLETED

Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study

NCT04892381

Lichen Planus

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases that primarily target muscle.

autoimmune Dermatomyositis (DM) is a rare inflammatory disease that mainly affects skin, muscle, and lung.

Inflammatory myopathies (IMs) often have distinct histopathologic features suggesting humorally mediated involvement of the microcirculation in dermatomyositis (DM), including early capillary deposition of the complement C5b-9 membranolytic attack complex (MAC) and secondary ischaemic changes; and CD8 T-cell-mediated and MHC1-restricted autoimmune attack of myofibers in polymyositis (PM) and inclusion body myositis.

Plexins are a conserved family of large proteins (\~200kDa) that are the canonical receptors for semaphorin molecules. Plexins are divided into four classes, A through D.

Recently, plexin and semaphorin molecules have been shown to control cell movement and cell-cell interaction in the immune system .

Extracellular vesicles (EVs) are lipid bilayer membrane vesicles that exist in various bodily fluids. EVs are released by normal, diseased, and transformed cells in vitro and in vivo and are capable of carrying lipids, proteins, mRNAs, non-coding RNAs, and even DNA. They are abundant in serum and plasma and have been a source of considerable interest as potential disease biomarkers. Normally, they maintain physiological functions by transferring biological information to neighboring cells and facilitating intercellular communication, but are also involved in the pathogenesis of numerous autoimmune diseases LC/MS analysis identified 1220 proteins in serum EVs. Of these, plexin D1 was enriched in those from PM/DM patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polymyositis Dermatomyositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

adult polymyositis and dermatomyositis

plexinD1

Intervention Type DIAGNOSTIC_TEST

evaluation of the serum level of plexinD1

juvenile dermatomyositis

plexinD1

Intervention Type DIAGNOSTIC_TEST

evaluation of the serum level of plexinD1

healthy controls

plexinD1

Intervention Type DIAGNOSTIC_TEST

evaluation of the serum level of plexinD1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

plexinD1

evaluation of the serum level of plexinD1

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult PM/DM patients .
2. Juvenile dermatomyositis patients.

Exclusion Criteria

* 1-Patients with other autoimmune diseases ( rheumatoid arthritis ,systemic lupus erythematosus, polyarteritis nodosa sarcoidosis, scleroderma, spondylarthritis and inflammatory bowel disease) 2-Patients with malignant tumors 3-Patients with active infection 4-Patients with severe heart, lung, and kidney dysfunction

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes